JAK2 and erythroleukemia: Of note, HEL cells are derived from an erythroleukemia patient33, featuring faster growth and resistant to JAK2 inhibitors in vitro, while SET2 cells are derived from an ET patient with leukemic transformation34, featuring slower growth and sensibility to JAK2 inhibitors in vitro.